Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Caplin Point Lab
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Caplin Point Lab

WEBSITE BSE:524742 NSE: CAPLIPOINT Inc. Year: 1990 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock

₹1770.9 4.5 | 0.3%

Last updated: 15:57

Consolidated Standalone

Last updated: 15:57

Caplin Point Lab Overview

Caplin Point Laboratories Ltd is a pharmaceutical company. It's product segments are Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Antibiotics, Pain Management and Anti-ulcers. The Company offers a number of products, including Tablets, Liquid Orals, Capsule, Inhalers, intravenous (IV) Infusion, Lyophilized Products, Softgel Capsules, Suppositories and Ovules, Powder for Injection, Dry syrup, Topicals, Liquid Injections, Branded Products, Dermo Cosmetics and Other Products. It additionally manufactures a variety of ointments, lot...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Caplin Point Lab Key Financials

Market Cap ₹13461 Cr.

Stock P/E 24.9

P/B 4

Current Price ₹1770.9

Book Value ₹ 437.5

Face Value 2

52W High ₹2397

Dividend Yield 0.34%

52W Low ₹ 1502.5

Edit Ratio

Caplin Point Lab Share Price

₹ | |

Volume
Price

Caplin Point Lab Quarterly Price

Quarterly Monthly
Show Value Show %

Caplin Point Lab Peer Comparison

Caplin Point Lab Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 410 436 453 459 483 493 502 510 534 543
Other Income 20 17 17 19 21 31 26 23 30 34
Total Income 430 453 471 478 504 524 528 533 564 576
Total Expenditure 273 293 308 307 318 331 334 332 345 353
Operating Profit 158 159 163 170 186 194 194 201 220 223
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 12 14 16 16 17 16 17 16 18 19
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 146 145 146 154 169 177 177 184 201 204
Provision for Tax 30 26 25 29 38 37 31 34 41 38
Profit After Tax 116 120 121 125 131 140 145 151 160 166
Adjustments -1 -3 0 -1 -0 -1 -3 2 -6 -2
Profit After Adjustments 115 117 122 124 131 139 143 153 154 164
Adjusted Earnings Per Share 15.1 15.4 16 16.3 17.2 18.3 18.8 20.1 20.3 21.6

Caplin Point Lab Profit & Loss

#(Fig in Cr.) Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 252 239 402 540 649 863 1061 1269 1467 1694 1937 2089
Other Income 3 4 10 13 19 41 28 39 57 67 96 113
Total Income 255 242 412 553 668 905 1089 1308 1523 1761 2034 2201
Total Expenditure 192 175 277 345 417 603 737 875 1026 1143 1291 1364
Operating Profit 63 68 135 208 251 301 352 433 497 618 743 838
Interest 1 0 1 1 1 0 2 1 1 1 1 0
Depreciation 8 7 13 19 23 32 37 47 45 53 66 70
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 53 60 121 188 227 269 314 386 451 564 677 766
Provision for Tax 12 14 25 44 50 54 62 77 74 103 136 144
Profit After Tax 41 46 96 145 177 215 251 308 377 461 541 622
Adjustments -0 -0 0 0 0 -0 -9 -9 -1 -4 -5 -9
Profit After Adjustments 41 46 96 145 177 215 242 300 376 457 536 614
Adjusted Earnings Per Share 5.4 6.1 12.7 19.2 23.3 28.4 32 39.6 49.6 60.2 70.6 80.8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 14% 15% 18% 23%
Operating Profit CAGR 20% 20% 20% 28%
PAT CAGR 17% 21% 20% 29%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -10% 42% 29% 24%
ROE Average 22% 23% 24% 35%
ROCE Average 26% 27% 28% 43%

Caplin Point Lab Balance Sheet

#(Fig in Cr.) Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 93 128 225 364 633 948 1186 1484 1880 2316 2850
Minority's Interest 0 0 0 0 0 9 18 26 27 31 36
Borrowings 1 1 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 10 13 19 28 23 25 17 13 2 8 13
Total Current Liabilities 125 125 113 109 86 144 143 208 268 331 306
Total Liabilities 229 267 358 500 743 1126 1364 1730 2177 2686 3206
Fixed Assets 113 144 152 169 227 273 305 287 280 453 546
Other Non-Current Assets 34 4 27 27 22 31 44 146 345 340 526
Total Current Assets 82 119 179 304 494 823 1015 1298 1552 1893 2134
Total Assets 229 267 358 500 743 1126 1364 1730 2177 2686 3206

Caplin Point Lab Cash Flow

#(Fig in Cr.) Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 27 45 67 91 77 151 221 232 151 178 139
Cash Flow from Operating Activities 50 42 68 66 83 45 269 337 271 318 432
Cash Flow from Investing Activities -23 -6 -36 -69 -100 -55 -29 -377 -218 -320 -335
Cash Flow from Financing Activities -9 -14 -7 -12 90 80 -24 -41 -28 -38 -38
Net Cash Inflow / Outflow 19 23 25 -14 73 70 215 -81 26 -40 59
Closing Cash & Cash Equivalent 45 68 91 77 151 221 436 151 171 134 194

Caplin Point Lab Ratios

# Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 5.43 6.06 12.65 19.15 23.34 28.42 32.03 39.56 49.57 60.18 70.57
CEPS(Rs) 6.55 7.05 14.4 21.64 26.44 32.61 38.12 46.88 55.6 67.79 79.88
DPS(Rs) 1 1.2 1.5 2 2.2 2.5 3 4 4.5 5 6
Book NAV/Share(Rs) 11.84 16.25 29.73 47.69 78.03 114.21 144.94 183.89 235.91 293.21 362.67
Core EBITDA Margin(%) 23.71 26.9 31.07 36.18 35.74 30.13 30.55 31.08 30.03 32.55 33.39
EBIT Margin(%) 21.59 25.3 30.24 35.01 35.06 31.25 29.7 30.45 30.83 33.36 34.96
Pre Tax Margin(%) 21.2 25.16 30.11 34.9 34.97 31.22 29.55 30.39 30.77 33.32 34.93
PAT Margin (%) 16.33 19.17 23.78 26.79 27.22 24.92 23.69 24.3 25.7 27.24 27.93
Cash Profit Margin (%) 19.66 22.3 27.09 30.31 30.83 28.58 27.17 27.99 28.77 30.39 31.33
ROA(%) 20.12 18.46 30.54 33.68 28.41 23.02 20.2 19.94 19.3 18.98 18.37
ROE(%) 55.78 43.13 54.97 49.43 37.14 29.58 25.65 24.77 23.68 22.97 21.72
ROCE(%) 71.11 55.41 69.03 64.08 45.59 33.35 28.82 28.77 26.85 26.92 26.22
Receivable days 4.17 10.4 18.62 53.72 80.37 82.19 87.41 85.74 88.48 100.92 110.7
Inventory Days 17 24.83 18.68 17.16 18.54 58.28 71.75 58.42 64.15 70.16 65.86
Payable days 98.32 146.5 132.54 132.42 97.76 55.04 59.05 80.02 84.89 96.31 105.88
PER(x) 34.23 33.39 30.68 29.92 17.24 9.93 12.62 17.19 12.04 21.89 28.38
Price/Book(x) 15.7 12.45 13.06 12.02 5.16 2.47 2.79 3.7 2.53 4.49 5.52
Dividend Yield(%) 0.54 0.59 0.39 0.35 0.55 0.89 0.74 0.59 0.75 0.38 0.3
EV/Net Sales(x) 5.41 6.12 7.07 7.88 4.51 2.34 2.55 3.75 2.8 5.62 7.59
EV/Core EBITDA(x) 21.7 21.54 21.08 20.45 11.66 6.71 7.7 11 8.28 15.41 19.78
Net Sales Growth(%) 45.46 -5.18 68.25 34.41 20.16 33.07 22.95 19.61 15.54 15.5 14.37
EBIT Growth(%) 49.44 11.1 101.14 55.59 20.36 18.61 16.84 22.62 16.97 25.01 19.85
PAT Growth(%) 58.59 11.29 108.66 51.45 22.07 21.82 16.9 22.68 22.22 22.4 17.27
EPS Growth(%) 58.76 11.52 108.85 51.38 21.9 21.76 12.67 23.52 25.32 21.4 17.25
Debt/Equity(x) 0.02 0.02 0 0 0 0.04 0.01 0 0 0 0
Current Ratio(x) 0.66 0.95 1.58 2.8 5.73 5.7 7.1 6.25 5.79 5.72 6.97
Quick Ratio(x) 0.55 0.8 1.38 2.54 5.3 4.05 5.85 5.15 4.72 4.62 5.88
Interest Cover(x) 56.11 179.35 235.08 309.72 391.22 843.86 198.25 552.17 579.65 724.63 1110.48
Total Debt/Mcap(x) 0 0 0 0 0 0.02 0.01 0 0 0 0

Caplin Point Lab Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 70.63 70.62 70.62 70.56 70.56 70.56 70.56 70.56 70.57 70.57
FII 3.07 2.85 3.34 3.37 3.7 4.86 5.73 6.17 6.48 6.56
DII 0.22 0.43 1.09 1.49 1.83 2.11 2.01 2.22 2.13 2.09
Public 26.08 26.1 24.95 24.57 23.91 22.47 21.7 21.05 20.82 20.79
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Caplin Point Lab News

Caplin Point Lab Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 23%
  • Company is almost debt free.

Cons

  • Debtor days have increased from 96.31 to 105.88days.
  • Stock is trading at 4 times its book value.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!